ADDORA-Low
Study details
Study purpose: Evaluation or Adalimumab mirror <2mg/L is sufficient for preserve remission
Symptoms/Diagnose: RA
Disease phase: Stable RA
Indication/Medication: >28 weeks stable on Adalimumab
Home > ADDORA-Low
Study purpose: Evaluation or Adalimumab mirror <2mg/L is sufficient for preserve remission
Symptoms/Diagnose: RA
Disease phase: Stable RA
Indication/Medication: >28 weeks stable on Adalimumab

Research on biomarkers for developing a flare in SLE

IgG4/IgG RNA ratio as a disease activity marker in vasculitis

Study of failing immune tolerance between mother and fetus as cause of pregnancy complications in SLE

Evaluation effect of Filgotinib on heart through cardiac MRI/CT in RA

Observational cohort study of Guselkumab (Tremfya) and anti- IL17 therapy in PSA
PO Box 7057
1007 MB Amsterdam
The Netherlands